Stanislav Lazarev, MD

Dr. Stanislav (Stas) Lazarev, MD, is an Assistant Professor and the Associate Program Director of the Radiation Oncology Residency Program at the Icahn School of Medicine at Mount Sinai in New York City. He provides patient care at both Mount Sinai Hospital and the New York Proton Center.

Dr. Lazarev specializes in the personalized treatment of central nervous system (CNS) tumors, including primary and metastatic brain and spinal cord tumors in both children and adults, leptomeningeal disease (LMD), pediatric tumors, and the re-irradiation of CNS, thoracic, and hepatobiliary tumors. His other major focus is the radiation treatment of thoracic and hepatobiliary tumors using proton beam therapy. His clinical expertise includes proton craniospinal irradiation (CSI) for LMD, proton re-irradiation, proton radiotherapy for pediatric cancers, and low-dose re-irradiation for recurrent pediatric diffuse intrinsic pontine gliomas (DIPG) and diffuse midline glioma, H3 K27-altered WHO Grade 4.

In recognition of his dedication to compassionate and effective communication, Dr. Lazarev was honored with the Cullman Family Award for Excellence in Provider Communication in 2024. Out of over 117,000+ providers surveyed nationwide, Dr. Lazarev was among 89 Mount Sinai providers who ranked in the top 5% nationally in provider communication, as measured by the Press Ganey 2023 patient experience surveys.

Dr. Lazarev’s commitment to education has also been recognized with the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award in both 2022 and 2024. Additionally, in 2023, he received the STAR Employee Award for his exceptional service and dedication to Mount Sinai’s core values.

His research focuses on proton craniospinal irradiation in LMD, re-irradiation for brain tumors, and proton therapy for pediatric cancers. He serves as the institutional principal investigator for the NRG Oncology BN012 clinical trial, a randomized phase III study comparing pre-operative versus post-operative stereotactic radiosurgery for resectable brain metastases. His work has been widely published in leading journals, including Nature Reviews Clinical Oncology, Neuro-Oncology, International Journal of Radiation Oncology, Biology, Physics, and Advances in Radiation Oncology.

Internationally, Dr. Lazarev is actively involved in the Brain Tumors in Latin America Program, an initiative of St. Jude Children’s Research Hospital. He participates in a weekly Global Pediatric CNS Tumor Board, collaborating with leading oncologists from the USA, Canada, Germany, and Spain to provide expertise on complex pediatric CNS cases from low- and middle-income countries in Central and South America. His clinical insights are regularly sought by colleagues worldwide.

Dr. Lazarev is fluent in Russian, Spanish, and Portuguese, proficient in French, has basic knowledge of Hebrew, and is currentlylearning Arabic to better communicate with his diverse patient population. He believes that speaking to patients in their native language fosters trust and improves the quality of care.

Beyond the clinic and academia, Dr. Lazarev is an influential thought leader. He contributes to TheMedNet.org and engages with the radiation oncology community on X.com (formerly Twitter), where his insights on neuro-oncology, CNS radiation oncology, and pediatric radiation oncology have attracted significant attention, with individual posts reaching up to 100,000 views.

Dr. Lazarev’s work reflects his dedication to advancing cancer care across all settings, from local clinical practice to national and international initiatives, ensuring that his expertise benefits diverse patient populations while driving innovations in radiation oncology.